ed living skin construct (APLIGRAF) accelerates complete closure of hard-to-heal venous ulcers.
Wound Repair Regen 1999;7:201-7.
260. Falanga V, Margolis D, Alvarez O, Auletta M, Maggiacomo F,
Altman M, et al. Rapid healing of venous ulcers and lack of clinical
rejection with an allogeneic cultured human skin equivalent. Human
Skin Equivalent Investigators Group. Arch Dermatol 1998;134:
293-300.
261. Zaulyanov L, Kirsner RS. A review of a bi-layered living cell treatment
(Apligraf) in the treatment of venous leg ulcers and diabetic foot ulcers. Clin Interv Aging 2007;2:93-8.
262. Hankin CS, Knispel J, Lopes M, Bronstone A, Maus E. Clinical and
cost efÔ¨Åcacy of advanced wound care matrices for venous ulcers.
J Manag Care Pharm 2012;18:375-84.
263. Mostow EN, Araway GD, Dalsing M, Hodde JP, King D. Effectiveness of an extracellular matrix graft (OASIS Wound Matrix) in the
treatment of chronic leg ulcers: A randomized clinical trial. J Vasc
Surg 2005;41:837-43.
264. Vuerstaek JD, Vainas T, Wuite J, Nelemans P, Neumann MH,
Veraart JC. State-of-the-art treatment of chronic leg ulcers: A randomized controlled trial comparing vacuum-assisted closure (V.A.C.)
with modern wound dressings. J Vasc Surg 2006;44:1029-37; discussion: 1038.
265. Ubbink DT, Westerbos SJ, Evans D, Land L, Vermeulen H. Topical
negative pressure for treating chronic wounds. Cochrane Database
Syst Rev 2008;3:CD001898.
266. Houghton PE, Kin